Skip to main content

Table 1 Baseline characteristics of the three studies used in the analysis

From: Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials

Variable PLCO SELECT SABOR SMD
n 31,495 35,507 1790  
Age (mean (SD)) 62.47 (5.27) 62.93 (6.80) 58.68 (9.63) 0.35
African American = yes (%) 1279 (4.1) 5256 (14.8) 173 (9.7) 0.25
BMI (mean (SD)) 27.61 (4.19) 28.59 (4.60) 28.17 (4.80) 0.15
Family history of cancer = yes (%) 2299 (7.4) 5929 (16.7) 424 (23.7) 0.31
Cancer diagnosis = yes (%) 2798 (8.9) 2550 (7.2) 198 (11.1) 0.09
Cancer grade (%)     0.28
 Low-grade cancer 935 (33) 1756 (69) 169 (85)  
 High-grade cancer (Gleason > 7) 375 (13) 146 (6) 22 (11)  
 Missing grade 1488 (53) 648 (25) 7 (4)  
DRE = suspicious (%) 2082 (6.6) 3 (0.0) 295 (16.5) 0.44
BPH = yes (%) 6463 (20.6) 5334 (15.0) 626 (35.0) 0.31
Baseline PSA (mean (SD)) 1.30 (0.88) 1.35 (0.94) 1.16 (0.79) 0.15
Follow-up years (median (IQR]) 11.7 [9.6, 12.9] 8.1 [6.1, 10.3] 9.02 [4.76, 13.16] 0.54
PCa follow-up (median (IQR]) 6.7 [3.5, 9.5] 4.2[2.3, 6.0] 5.62 [3.17, 8.32] 0.49
No PCa follow-up (median (IQR]) 12.5 [10.5, 12.9] 8.4[6.5, 10.4] 9.74 [5.28, 13.44] 0.60
  1. All omnibus p-values were less than 0.001. SMD is the average standardized mean difference for pairwise comparisons